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INTRODUCTION
Polymyositis is an inflammatory muscle disease character-
ized clinically by proximal muscle weakness and histologically
by chronic inflammation of the affected muscles. It has
already been well documented that interferon , due to its abili-
ty to modulate immunity, can induce or exacerbate autoim-
mune disease (1). We report a case of a 33-yr-old male patient
with chronic hepatitis B who developed polymyositis and
dilated cardiomyopathy associated with interferon  therapy.
CASE
This 33 yr-old male patient visited our department due
to proximal muscle weakness. He has been complaining of
easy fatigability and was diagnosed of hepatitis B at other
hospital before visiting our department. His mother and 5
siblings were all positive for hepatitis B virus. To treat hep-
atitis B, interferon  with a dosage of 5×10
6 units was com-
menced three times per week for six weeks until the proxi-
mal muscle weakness developed. He did not experience any
muscle weakness or pain prior to the interferon  treatment.
Laboratory studies revealed initial CPK and LDH levels of
11,620 U/L and 647 U/L, respectively. Initial serum ALT and
AST levels were 180 IU/mL and 79 IU/mL, respectively.
Autoantibodies such as anti-DNA (Crithidia luciliae immun-
ofluorescence test), anti-nRNP, and anti-Jo-1 were all nega-
tive. Viral markers were as follows, hepatitis Bs Ag/Ab (+/-),
hepatitis Be Ag/Ab (+/-), hepatitis Bc Ab (-), HBV-DNA
(positive: 7,300 pg/mL), which collectively suggested hep-
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A Case of Polymyositis with Dilated Cardiomyopathy Associated with
Interferon   Treatment for Hepatitis B
Polymyositis is a rare complication of interferon  treatment as a result of immune-
modulating role of the drug itself. In this case, interferon  induced polymyositis
and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic
hepatitis B. To treat hepatitis B, interferon  was administered until the proximal
muscle weakness developed. Thereafter, sixteen cycles of immunoglobulin treat-
ment (400 mg/kg) along with corticosteroids were instituted and led to an improve-
ment in subjective symptoms with decreases in level of CPK and LDH. However,
dilated cardiomyopathy has not improved in spite of the cessation of interferon
treatment. Unlike the persistently elevated serum HBV DNA level, the serum ALT
and AST levels have gradually decreased. Our case shows that clinical symp-
toms of polymyositis improved with steroid and immunoglobulin treatment with-
out deterioration of the hepatitis B. To our knowledge, this is the first case of poly-
myositis associated with dilated cardiomyopathy after the administration of inter-
feron in a patient with hepatitis B.
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Fig. 1. Intrafascicular (endomyosial) infiltration of mononuclear
inflammatory cells is shown, which is a characteristic finding of
inflammatory myopathy (H&E, × 400).142 S.-W. Lee, K.-C. Kim, D.-H Oh, et al.
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Fig. 2. A: M-mode echocardiography showing dilated left ventricular wall with decreased left ventricular wall motion. B: Parasternal long
axis view showing dilated left ventricle, which corresponds to M mode findings.
atitis B in active replicative state. The muscle biopsy was done
and revealed scattered degeneration of muscle fibers and regen-
erating basophilic fibers at stage of regeneration. In addition,
there was focal intrafascicular infiltration of mononuclear
inflammatory cells (Fig. 1). These histopathologic findings
were compatible with those of idiopathic inflammatory myo-
pathy. Unlike the earlier chest radiography, which were nor-
mal, cardiomegaly was noted on the following chest radiog-
raphy. Echocardiography was performed and showed decreased
left ventricular systolic function with an ejection fraction of
37%, as well as dilated left ventricle with decreased wall
motion of entire left ventricle (Fig. 2). He received multiple
administrations of interferon  treatment before polymyosi-
tis has developed, and despite well-documented report that
corticosteroid is the mainstay for treating polymyositis, 6
cycles of monthly-based immunoglobulin treatment (400 mg/
kg) were tried, without effect. Azathioprine (100 mg) and
cyclosporin (300 mg), which were administered for four
months after the cessation of immunoglobulin treatment,
resulted in no improvement. Thereafter, additional 10 cycles
of monthly-based immunoglobulin treatment (400 mg/kg)
with prednisolone (1 mg/kg) were instituted which made
CPK and LDH gradually decreased to 1,412 U/L and 373
U/L, respectively. These responses seemed to be temporary
rather than permanent. At present, the serum CPK and
LDH levels have further decreased but still high despite the
continued treatment and the gradual improvement of mus-
cular weakness. Regarding the hepatitis B, serum ALT and
AST have decreased to 78 IU/mL and 38 IU/mL, respective-
ly. However, HBV DNA level is 11,300 pg/mL, indicating
active replication of Hepatitis B virus. In addition, the dilated
cardiomyopathy with decreased cardiac output has slowly
worsened since the first blow-out of the disease.
DISCUSSION
Interferons are proteins produced by the cells as a defen-
sive response to virus and are important modulators of the
immune response. They are well-documented to be effective
in treating HBV infection by improving viral titers and liver
enzyme elevations. However, interferons can cause wide range
of side effects from the very common flu-like symptoms to
more severe psychiatric, hematologic and pulmonary effects
that limit the tolerable dose, and appear to be closely involved
in many aspects of the pathogenesis of autoimmunity (1-5)
such as overexpression of MHC class I, II molecules, produc-
tion of pathogenic antibodies, and overexpression of bcl-2
oncoprotein. However, the exact mechanisms whereby inter-
feron contributes to the development of autoimmune disease
are at the moment unclear (6, 7). A few cases of polymyosi-
tis associated with interferon therapy have been described in
the literature, and showed that after the discontinuation of
interferon, the muscular weakness gradually recovered with
or without immunosuppressive treatment (8, 9). In addition,
cardiotoxicity of interferon has been well-documented includ-
ing cardiac arrhythmia, dilated cardiomyopathy, and ischemic
heart disease as common presentations. Usually, these car-
diac manifestations were reversible following the cessation
of the interferon therapy (10).
Although hepatitis B virus itself can cause polymyositis
(11-13), it is unlikely that the polymyositis in this patientInterferon induced  Polymyositis  143
was virus-related in terms of time-sequence: the patient him-
self had been free of any muscle-related symptoms despite
long history of hepatitis B and the polymyositis developed
after the use of interferon  .
The patient did not recover from polymyositis after the
withdrawal of the interferon  . In addition, the immunoglob-
ulin treatment alone failed to bring improvement in the
polymyositis, which responded only to the high dose of steroid
along with the immunoglobulin. Although steroid is the
treatment of choice for polymyositis, immunoglobulin was
chosen for initial treatment due to the concerns that the steroid
might adversely affect the replicative activity of hepatitis B
virus (14). In this patient, steroid as well as azathioprine and
cyclosporin was administered. Although potential for symp-
tomatic and virologic improvement was needed to be bal-
anced with that for the adverse effects on proliferation of the
virus, the immunosuppressive treatment was inevitable since
multiple cycles of sole immunoglobulin had failed. As the
patient worried about changes in appearance, azathioprine
and cyclosporin were chosen instead of corticosteroids, which
is the treatment of choice for polymyositis. After the admin-
istration of steroid, active replication of hepatitis B virus was
noticed but did not lead to any sign of further hepatic dam-
age. Unlike usual cases, dilated cardiomyopathy gradually
aggravated in spite of the cessation of interferon treatment.
Given that cardiomyopathy developed after the interferon 
treatment, it is highly probable that the cardiomyopathy in
this patient was due to the interferon-induced polymyositis
cardiotoxicity rather than the virus itself. In addition, weight
gain, which is assumed to be partly due to the steroid, might
have had potential detrimental influence on the cardiac func-
tion.
To our knowledge, this is the first case of polymyositis asso-
ciated with dilated cardiomyopathy after the administration
of interferon in a patient with hepatitis B.
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